Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK228 + Brentuximab Vedotin in Relapsed/Refractory CD30+ Lymphomas
NCT03205891Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2018
- Primary completion
- Mar 2021
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of sapanisertib in classical Hodgkin lymphoma (cHL), anaplastic large cell lymphoma (ALCL) and peripheral T-cell lymphoma (PTCL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety of Brentuximab Vedotin Administered with TAK228 Assessed by Dose Limiting Toxicities at 21 days and Maximum Tolerated Dose of Brentuximab Vedotin plus TAK228 at 21 days. Planned start Mar 2018; status: withdrawn.
02
Drugs
sapanisertib
03
Conditions
classical Hodgkin lymphoma (cHL)anaplastic large cell lymphoma (ALCL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03205891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03205891.